BR112021024469A2 - Métodos para tratamento de câncer com o uso de inibidores de prmt5 - Google Patents

Métodos para tratamento de câncer com o uso de inibidores de prmt5

Info

Publication number
BR112021024469A2
BR112021024469A2 BR112021024469A BR112021024469A BR112021024469A2 BR 112021024469 A2 BR112021024469 A2 BR 112021024469A2 BR 112021024469 A BR112021024469 A BR 112021024469A BR 112021024469 A BR112021024469 A BR 112021024469A BR 112021024469 A2 BR112021024469 A2 BR 112021024469A2
Authority
BR
Brazil
Prior art keywords
methods
days
prmt5
administering
subsequent
Prior art date
Application number
BR112021024469A
Other languages
English (en)
Inventor
T Greway Anthony
Dirk Brehmer
S J Mannens Geert
Joy Millar Quinn Hillary
Hong Xie
Josh Lauring
Junguo Zhou
Elizabeth Packman Kathryn
Nahor Haddish-Berhane
Tongfei Wu
Yue Guo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021024469A2 publication Critical patent/BR112021024469A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos para tratamento de câncer com o uso de inibidores de prmt5. a presente invenção refere-se a métodos para tratar um paciente humano diagnosticado com um câncer, compreendendo a administração de uma quantidade terapeuticamente eficaz de um inibidor de prmt5 (proteína arginina metiltransferase 5), sendo que certos métodos compreendem (i) administrar ao paciente doses iniciais de ao menos cerca de 0,1 mg, por dia, do inibidor de prmt5 que é (1s,2r,3s,5r)-3-(2-(2-amino-3-bromoquinolin-7-il)etil)-5-(4-amino-7h-pirrolo[2,3-d]pirimidin-7-il)ciclopentano-1,2-diol, ou um solvato ou sal de adição farmaceuticamente aceitável do mesmo, durante um período de dosagem inicial de cerca de 5 a cerca de 21 dias; e (ii) administrar ao paciente doses subsequentes de ao menos cerca de 0,1 mg, por dia, do inibidor de prmt5 durante um ou mais períodos de dosagem subsequentes de cerca de 5 a cerca de 21 dias cada. nesses métodos, um primeiro período de dosagem subsequente é separado, em termos de tempo, do período de dosagem inicial por ao menos cerca de 5 dias e os períodos de dosagem subsequentes são separados um do outro, em termos de tempo, por ao menos cerca de 5 dias.
BR112021024469A 2019-06-06 2020-06-05 Métodos para tratamento de câncer com o uso de inibidores de prmt5 BR112021024469A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858076P 2019-06-06 2019-06-06
EP19193850 2019-08-27
PCT/EP2020/065639 WO2020245365A1 (en) 2019-06-06 2020-06-05 Methods of treating cancer using prmt5 inhibitors

Publications (1)

Publication Number Publication Date
BR112021024469A2 true BR112021024469A2 (pt) 2022-01-18

Family

ID=70922068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024469A BR112021024469A2 (pt) 2019-06-06 2020-06-05 Métodos para tratamento de câncer com o uso de inibidores de prmt5

Country Status (15)

Country Link
US (2) US11571437B2 (pt)
EP (1) EP3980019A1 (pt)
JP (1) JP2022535406A (pt)
KR (1) KR20220017989A (pt)
CN (1) CN113966232A (pt)
AU (1) AU2020286961A1 (pt)
BR (1) BR112021024469A2 (pt)
CA (1) CA3142825A1 (pt)
IL (1) IL288665A (pt)
JO (1) JOP20210320A1 (pt)
MA (1) MA56095A (pt)
MX (1) MX2021014944A (pt)
SG (1) SG11202112439YA (pt)
TW (1) TW202112375A (pt)
WO (1) WO2020245365A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022153161A1 (en) * 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN115161341B (zh) * 2022-06-10 2023-07-21 中国人民解放军军事科学院军事医学研究院 一种胃窦浸润性肠型胃癌小鼠模型的构建方法与应用
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7034147B2 (en) 2001-11-29 2006-04-25 Irm Llc Nucleoside analog libraries
MXPA04008008A (es) 2002-02-19 2005-03-23 Cv Therapeutics Inc Agonistas parciales y completos de receptores de adenosina a1.
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
WO2005005450A1 (ja) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. 環状ビスジヌクレオシドの合成方法
CA2548283A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
EP2043635A2 (en) 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
CA2737661C (en) 2008-09-23 2019-08-20 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
CA2784596A1 (en) 2009-12-18 2011-06-23 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
MX2013006951A (es) 2010-12-16 2013-10-03 Abbvie Inc Compuestos antivirales.
US9284343B2 (en) 2011-04-04 2016-03-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
US20140100184A1 (en) 2012-08-31 2014-04-10 Baylor College Of Medicine Selective inhibitors of histone methyltransferase dot1l
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100716A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2975938A4 (en) * 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
CA2935944A1 (en) 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
HUE045748T2 (hu) 2014-07-01 2020-01-28 Millennium Pharm Inc Heteroaril vegyületek mint SUMO aktiváló enzimek inhibitorai
CR20170384A (es) 2015-02-24 2017-11-16 Pfizer Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
CN115626935A (zh) 2016-10-03 2023-01-20 詹森药业有限公司 用作prmt5抑制剂的单环和双环系统取代的卡巴核苷类似物
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2019110734A1 (en) 2017-12-08 2019-06-13 Janssen Pharmaceutica Nv Novel spirobicyclic analogues

Also Published As

Publication number Publication date
WO2020245365A1 (en) 2020-12-10
CN113966232A (zh) 2022-01-21
KR20220017989A (ko) 2022-02-14
US20200384006A1 (en) 2020-12-10
US20230241087A1 (en) 2023-08-03
JOP20210320A1 (ar) 2023-01-30
SG11202112439YA (en) 2021-12-30
EP3980019A1 (en) 2022-04-13
MX2021014944A (es) 2022-01-24
US11571437B2 (en) 2023-02-07
TW202112375A (zh) 2021-04-01
AU2020286961A1 (en) 2022-02-03
JP2022535406A (ja) 2022-08-08
MA56095A (fr) 2022-04-13
IL288665A (en) 2022-02-01
CA3142825A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
BR112021024469A2 (pt) Métodos para tratamento de câncer com o uso de inibidores de prmt5
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112022012641A2 (pt) Compostos tricíclicos substituídos
Bibi et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
BR112012029959A2 (pt) compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
US20190201402A1 (en) Compositions and Methods for the Treatment of Prader-Willi Syndrome
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
CY1124346T1 (el) ΠΑΡΑΓΩΓΑ ΧΡΩΜΑΝΙΟΥ, ΙΣΟΧΡΩΜΑΝΙΟΥ ΚΑΙ ΔΙΥΔΡΟΪΣΟΒΕΝΖΟΦΟΥΡΑΝΙΟΥ ΩΣ mGluR2-APNHTIKOI ΑΛΛΟΣΤΕΡΙΚΟΙ ΔΙΑΜΟΡΦΩΤΕΣ, ΣΥΝΘΕΣΕΙΣ, ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ
EA202190532A1 (ru) Ингибиторы аргиназы и способы их применения
Liu et al. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021022602A2 (pt) Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton
Kong et al. Sirtuins as potential therapeutic targets for hepatitis B virus infection
Zhao et al. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis
Wang et al. Osteoclasts and osteoarthritis: Novel intervention targets and therapeutic potentials during aging
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
EP4389218A3 (en) Composition for treating joint disease and kit containing same